Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viatris Inc.

Alnylam vs. Viatris: A Decade of R&D Investment

__timestampAlnylam Pharmaceuticals, Inc.Viatris Inc.
Wednesday, January 1, 2014190249000581800000
Thursday, January 1, 2015276495000671900000
Friday, January 1, 2016382392000876700000
Sunday, January 1, 2017390635000857900000
Monday, January 1, 2018505420000822200000
Tuesday, January 1, 2019655114000778200000
Wednesday, January 1, 2020654819000512600000
Friday, January 1, 2021792156000681000000
Saturday, January 1, 2022883015000662200000
Sunday, January 1, 20231004415000910700000
Monday, January 1, 20241126232000
Loading chart...

In pursuit of knowledge

Innovation Spending: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, innovation is key. Alnylam Pharmaceuticals, Inc. and Viatris Inc. have been at the forefront of this race, each with distinct strategies. Over the past decade, Alnylam has consistently increased its research and development (R&D) spending, culminating in a 428% rise from 2014 to 2023. This aggressive investment underscores their commitment to pioneering RNA interference therapeutics. In contrast, Viatris Inc., formed in 2020, has maintained a steady R&D expenditure, reflecting its focus on leveraging existing products and markets. By 2023, Alnylam's R&D expenses surpassed Viatris by approximately 10%, highlighting their divergent paths. This comparison not only showcases the dynamic nature of pharmaceutical innovation but also emphasizes the strategic choices companies make to stay ahead. As the industry evolves, these spending patterns will likely shape the future of healthcare breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025